In patients with cancer, TReg cells are continuously exposed to tumour antigen (TA), either directly or through the tumour micro-environment which in turn, results in high levels of ICOS expression as has been demonstrated in melanoma and prostate cancer [7], [43]. The gene discussed is ICOS; the disease is prostate carcinoma.